Mendes C, Kiffer C R V, Blosser-Middleton R S, Jones M E, Karlowsky J A, Barth A, Rossi F, Andrade S, Sader H S, Thornsberry C, Sahm D F
Fleury Medical Diagnostic Centre, Sao Paulo, Brazil.
Clin Microbiol Infect. 2004 Jun;10(6):521-6. doi: 10.1111/j.1469-0691.2004.00870.x.
The GLOBAL (Global Landscape On Bactericidal Activity of Levofloxacin) Surveillance programme monitored antimicrobial susceptibility patterns of the key respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected in Brazil during 1997-1998, 1999-2000 and 2001-2002. Penicillin and azithromycin resistance among S. pneumoniae strains increased from 1997-1998, reaching 7.9% and 9.5%, respectively, in 2001-2002. Although decreasing by 4.9% since the previous study, trimethoprim-sulphamethoxazole resistance remained high at 33.7%. Concurrent resistance to penicillin, azithromycin and trimethoprim-sulphamethoxazole was seen in 2.9% of the S. pneumoniae isolates collected. Levofloxacin remained extremely active against S. pneumoniae, with 0.3% resistance reported in 1997-1998 and 0% resistance in 1999-2000 and 2001-2002. beta-Lactamase production in H. influenzae was > 10% in all three studies, with correspondingly high rates of ampicillin resistance. Trimethoprim-sulphamethoxazole was the least active agent tested against H. influenzae, with resistance rates of > 40% recorded in all three studies. All H. influenzae isolates were susceptible to cefuroxime, ceftriaxone, azithromycin and levofloxacin. Of the M. catarrhalis isolates, 98.0% in 1997-1998, 98.0% in 1999-2000 and 81.8% in 2001-2002 were beta-lactamase-positive. The continued high prevalence of antimicrobial resistance in Brazil underscores the importance of current surveillance initiatives. Levofloxacin, a fluoroquinolone prescribed widely for respiratory tract infections, continued to show potent activity against key respiratory pathogens.
全球(左氧氟沙星杀菌活性全球概况)监测项目对1997 - 1998年、1999 - 2000年和2001 - 2002年期间在巴西收集的主要呼吸道病原体肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的抗菌药物敏感性模式进行了监测。肺炎链球菌菌株对青霉素和阿奇霉素的耐药性自1997 - 1998年起上升,在2001 - 2002年分别达到7.9%和9.5%。尽管自上次研究以来下降了4.9%,但甲氧苄啶 - 磺胺甲恶唑的耐药率仍高达33.7%。在收集的肺炎链球菌分离株中,有2.9%同时对青霉素、阿奇霉素和甲氧苄啶 - 磺胺甲恶唑耐药。左氧氟沙星对肺炎链球菌仍具有极强的活性,1997 - 1998年报告的耐药率为0.3%,1999 - 2000年和2001 - 2002年为0%。在所有三项研究中,流感嗜血杆菌产生β - 内酰胺酶的比例均>10%,氨苄西林耐药率相应较高。甲氧苄啶 - 磺胺甲恶唑是针对流感嗜血杆菌测试的活性最低的药物,在所有三项研究中记录的耐药率均>40%。所有流感嗜血杆菌分离株对头孢呋辛、头孢曲松、阿奇霉素和左氧氟沙星敏感。在卡他莫拉菌分离株中,1997 - 1998年为98.0%、1999 - 2000年为98.0%、2001 - 2002年为81.8%的菌株β - 内酰胺酶呈阳性。巴西抗菌药物耐药性的持续高流行凸显了当前监测举措的重要性。左氧氟沙星是一种广泛用于呼吸道感染的氟喹诺酮类药物,对主要呼吸道病原体继续显示出强效活性。